Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.76% |
| 2 | Technology | 16.41% |
| 3 | Consumer Staples | 10.58% |
| 4 | Consumer Discretionary | 10.13% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HIMX
1051
Himax Technologies
HIMX
$2.56B
| $13.5M | 0.01% |
3,263,126
-69,251
| -2% | -$224K |
|
1052
Standard BioTools
LAB
$312M
| $13.5M | 0.01% |
3,366,000
+178,818
| +6% | +$623K |
|
1053
Center Bancorp
CNOB
$1.81B
| $13.5M | 0.01% |
834,856
-100,071
| -11% | -$1.43M |
|
|
SP
1054
DELISTED
SP Plus Corporation
SP
| $13.5M | 0.01% |
649,700
+11,900
| +2% | +$245K |
|
|
FLG
1055
Flagstar Bank National Association
FLG
$5.9B
| $13.4M | 0.01% |
439,494
-211,958
| -33% | -$6.37M |
|
1056
Sensata Technologies
ST
$6.72B
| $13.4M | 0.01% |
360,800
+35,200
| +11% | +$1.24M |
|
1057
York Water
YORW
$528M
| $13.4M | 0.01% |
279,736
-36,400
| -12% | -$1.58M |
|
1058
Northwest Bancshares
NWBI
$2.31B
| $13.4M | 0.01% |
1,305,868
+473,023
| +57% | +$4.87M |
|
1059
Dover
DOV
$28B
| $13.3M | 0.01% |
138,100
-227,700
| -62% | -$21M |
|
|
DMC
1060
Del Monte Corp
DMC
$1.42B
| $13.3M | 0.01% |
541,300
-155,500
| -22% | -$4.07M |
|
1061
Valmont Industries
VMI
$9.52B
| $13.2M | 0.01% |
116,400
+107,300
| +1,179% | +$11.9M |
|
1062
Goldman Sachs Access Treasury 0-1 Year ETF
GBIL
$7.59B
| $13.2M | 0.01% |
131,500
+127,081
| +2,876% | +$12.8M |
|
1063
Chesapeake Utilities
CPK
$3.25B
| $13.2M | 0.01% |
157,100
-54,450
| -26% | -$4.73M |
|
|
SWIR
1064
DELISTED
Sierra Wireless
SWIR
| $13.1M | 0.01% |
1,462,100
+10,200
| +0.7% | +$87.1K |
|
|
EIGI
1065
DELISTED
Endurance International Group Holdings, Inc.
EIGI
| $13.1M | 0.01% |
3,256,413
-349,280
| -10% | -$1.03M |
|
1066
Home Depot
HD
$341B
| $13.1M | 0.01% |
52,352
+7,780
| +17% | +$1.78M |
|
1067
T. Rowe Price
TROW
$23.8B
| $13M | 0.01% |
105,500
-55,800
| -35% | -$6.36M |
|
1068
Xenon Pharmaceuticals
XENE
$6.31B
| $13M | 0.01% |
1,035,277
+247,200
| +31% | +$3.15M |
|
1069
WisdomTree
WT
$3.44B
| $13M | 0.01% |
3,739,077
-215,702
| -5% | -$655K |
|
|
FLIC
1070
DELISTED
First of Long Island Corp
FLIC
| $13M | 0.01% |
793,381
-34,300
| -4% | -$526K |
|
1071
Vanguard Tax-Exempt Bond Index Fund
VTEB
$46.1B
| $13M | 0.01% |
+239,395
| New | +$12.8M |
|
1072
SPDR Gold Trust
GLD
$142B
| $13M | 0.01% |
+77,400
| New | +$12.5M |
|
1073
Carrier Global
CARR
$52.2B
| $13M | 0.01% |
+582,900
| New | +$10.8M |
|
|
XLRN
1074
DELISTED
Acceleron Pharma
XLRN
| $12.9M | 0.01% |
135,600
-64,000
| -32% | -$6.17M |
|
|
LN
1075
DELISTED
LINE Corporation
LN
| $12.9M | 0.01% |
257,755
+97,277
| +61% | +$4.81M |
|
Similar funds
Jim Simons's Q2 2020 Portfolio in Review
As of Q2 2020, Jim Simons held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Jim Simons withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,366 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 26% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Jim Simons opened a new position in Uber worth $187M.
- Jim Simons's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Jim Simons added most to Zoom in Q2 2020, an estimated $806M increase.
- Jim Simons's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Jim Simons fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Jim Simons's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Jim Simons opened 584 new positions and closed 596 in Q2 2020.
- Jim Simons's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.